MX2011010449A - Derivados de oxadiazol. - Google Patents

Derivados de oxadiazol.

Info

Publication number
MX2011010449A
MX2011010449A MX2011010449A MX2011010449A MX2011010449A MX 2011010449 A MX2011010449 A MX 2011010449A MX 2011010449 A MX2011010449 A MX 2011010449A MX 2011010449 A MX2011010449 A MX 2011010449A MX 2011010449 A MX2011010449 A MX 2011010449A
Authority
MX
Mexico
Prior art keywords
oxadiazole derivatives
compounds
useful
formula
treatment
Prior art date
Application number
MX2011010449A
Other languages
English (en)
Inventor
Wolfgang Sauer
Anna Quattropani
Agnes Bombrun
Stefano Crosignani
Cyril Montagne
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of MX2011010449A publication Critical patent/MX2011010449A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos de fórmula I: (ver fórmula (I)) donde R1, R2, Ra, Rb, W, Q y S poseen los significados provistos en la reivindicación 1; los compuestos son útiles, por ejemplo, en el tratamiento de trastornos autoinmunes, como, por ejemplo, la esclerosis múltiple.
MX2011010449A 2009-04-03 2010-03-29 Derivados de oxadiazol. MX2011010449A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09157301A EP2241558A1 (en) 2009-04-03 2009-04-03 Oxadiazole derivatives
US16977309P 2009-04-16 2009-04-16
PCT/EP2010/054100 WO2010115751A2 (en) 2009-04-03 2010-03-29 Oxadiazole derivatives

Publications (1)

Publication Number Publication Date
MX2011010449A true MX2011010449A (es) 2011-11-18

Family

ID=40792794

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011010449A MX2011010449A (es) 2009-04-03 2010-03-29 Derivados de oxadiazol.
MX2011010451A MX2011010451A (es) 2009-04-03 2010-03-29 Derivados de oxadiazol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011010451A MX2011010451A (es) 2009-04-03 2010-03-29 Derivados de oxadiazol.

Country Status (16)

Country Link
US (2) US8802704B2 (es)
EP (3) EP2241558A1 (es)
JP (2) JP5833538B2 (es)
KR (2) KR20120002606A (es)
CN (2) CN102803238B (es)
AR (2) AR076188A1 (es)
AU (2) AU2010233932B2 (es)
BR (2) BRPI1013422A2 (es)
CA (2) CA2755918C (es)
EA (2) EA020691B1 (es)
ES (2) ES2652183T3 (es)
IL (2) IL215497B (es)
MX (2) MX2011010449A (es)
SG (2) SG174449A1 (es)
WO (2) WO2010112461A1 (es)
ZA (2) ZA201106854B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
SI2628733T1 (sl) 2010-10-14 2015-10-30 Daiichi Sankyo Company, Limited Derivati acilbenzena
MX2014008790A (es) 2012-01-18 2014-10-13 Daiichi Sankyo Co Ltd Derivado de fenilazol sustituido.
CA2876215A1 (en) 2012-07-02 2014-01-09 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
CN105051037B (zh) 2013-02-20 2018-05-18 Lg化学株式会社 鞘氨醇-1-磷酸酯受体激动剂、其制备方法以及包含其作为活性剂的药物组合物
CN103450171B (zh) * 2013-09-22 2015-07-08 苏州康乃德生物医药有限公司 一种免疫调节化合物、其用途和包含其的药物组合物
JP6615876B2 (ja) * 2014-06-26 2019-12-04 モナシュ ユニヴァーシティ 酵素相互作用薬剤
CA3003132A1 (en) * 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy
WO2018187479A1 (en) 2017-04-04 2018-10-11 Case Western Reserve University Method of modulating ribonucleotide reductase
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof
CN107827837B (zh) * 2017-11-21 2021-09-24 苏州朗科生物技术股份有限公司 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用
CN109956912B (zh) * 2017-12-26 2021-10-22 中国医学科学院药物研究所 含二苯基噁二唑的羧酸类化合物、其制备方法及医药用途
CN109761827A (zh) * 2019-02-18 2019-05-17 湖南科瑞生物制药股份有限公司 一种n-苄基乙醇胺的制备方法
CN110987847B (zh) * 2019-12-11 2021-02-19 苏州今蓝纳米科技有限公司 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用
CN116041277A (zh) * 2023-01-18 2023-05-02 中国药科大学 苯基和联苯基取代的五元杂环类化合物及其制备方法、药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062248A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
JP4773972B2 (ja) * 2003-12-17 2011-09-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
AU2006256968A1 (en) * 2005-06-08 2006-12-14 Novartis Ag Polycyclic oxadiazoles or I soxazoles and their use as SIP receptor ligands
JP2009269819A (ja) * 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
BRPI0717656A2 (pt) * 2006-09-29 2014-04-29 Novartis Ag Derivados de diaril oxadiazol
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
GB0625648D0 (en) * 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
DK2125797T3 (da) * 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
EP2014653A1 (en) * 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
AU2008306885B2 (en) * 2007-10-04 2013-12-05 Merck Serono S.A. Oxadiazole derivatives
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives

Also Published As

Publication number Publication date
US8802704B2 (en) 2014-08-12
WO2010115751A3 (en) 2010-12-16
EP2241558A1 (en) 2010-10-20
US8815919B2 (en) 2014-08-26
CN102803238B (zh) 2015-09-30
AR076188A1 (es) 2011-05-26
BRPI1015048A2 (pt) 2019-09-24
AU2010230314B2 (en) 2016-07-21
JP2012522745A (ja) 2012-09-27
AU2010233932B2 (en) 2016-10-13
ZA201106855B (en) 2012-11-28
WO2010112461A1 (en) 2010-10-07
EP2414341A2 (en) 2012-02-08
ES2652183T3 (es) 2018-01-31
EA201171211A1 (ru) 2012-05-30
CN102803238A (zh) 2012-11-28
EP2414341B1 (en) 2017-09-13
CA2755918A1 (en) 2010-10-14
AU2010230314A1 (en) 2011-10-13
MX2011010451A (es) 2011-11-18
JP5833538B2 (ja) 2015-12-16
US20120035226A1 (en) 2012-02-09
BRPI1013422A2 (pt) 2016-04-05
EP2414342A1 (en) 2012-02-08
SG174449A1 (en) 2011-10-28
IL215497A0 (en) 2011-12-29
CA2755918C (en) 2018-02-20
ZA201106854B (en) 2012-11-28
IL215497B (en) 2018-12-31
KR20120002606A (ko) 2012-01-06
CA2755928A1 (en) 2010-10-07
CN102459206A (zh) 2012-05-16
US20120022109A1 (en) 2012-01-26
EA201171210A1 (ru) 2012-05-30
EA020691B1 (ru) 2015-01-30
AU2010233932A1 (en) 2011-10-13
ES2639028T3 (es) 2017-10-25
IL215498A (en) 2017-11-30
EP2414342B1 (en) 2017-05-31
CA2755928C (en) 2017-06-20
IL215498A0 (en) 2011-12-29
SG174448A1 (en) 2011-10-28
JP5833537B2 (ja) 2015-12-16
WO2010115751A2 (en) 2010-10-14
AR076187A1 (es) 2011-05-26
JP2012522744A (ja) 2012-09-27
KR20110135987A (ko) 2011-12-20

Similar Documents

Publication Publication Date Title
MX2011010449A (es) Derivados de oxadiazol.
MX2010003612A (es) Derivados de oxadiazol.
MY159575A (en) Dihydroorotate dehydrogenase inhibitors
MX2010003614A (es) Compuestos de diarilo oxadiazol.
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
IN2012DN01233A (es)
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
NZ705135A (en) Heteroaryl compounds and methods of use thereof
EA201070238A1 (ru) Соединения пиримидина
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
GB0625648D0 (en) Compounds
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
MX2012004525A (es) Compuestos.
IL206514A (en) History of triazole oxadiazole, their preparation and their pharmaceutical preparations
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
TW200700064A (en) Novel compounds
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2011012533A (es) Espiro-epoxidos como productos intermedios.
TN2011000355A1 (en) Novel microbiocides
MX2010009837A (es) Tiazolil-dihidro-indazoles.
DE602007007934D1 (en) Imidazoazephinonverbindungen
MX2009013126A (es) Nuevos compuestos 892.

Legal Events

Date Code Title Description
FG Grant or registration